Free Trial
NASDAQ:CAPS

Capstone Therapeutics Q1 2026 Earnings Results & Report

Capstone Therapeutics logo
$1.74 -0.01 (-0.29%)
As of 01:06 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Capstone Therapeutics missed analyst earnings expectations but beat on revenue in its Q1 2026 results, released May 20, 2026. The company reported EPS of -$6.30 versus the -$5.70 consensus estimate, while revenue of $12.64 million topped the $10.80 million estimate by $1.84 million.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Capstone Therapeutics EPS Results

Actual EPS
-$6.30
Consensus EPS
-$5.70
Beat/Miss
Missed by -$0.60
One Year Ago EPS
N/A

Capstone Therapeutics Revenue Results

Actual Revenue
$12.64 million
Expected Revenue
$10.80 million
Beat/Miss
Beat by +$1.84 million
YoY Revenue Growth
N/A

Capstone Therapeutics Q1 2026 Earnings FAQ

Capstone Therapeutics (NASDAQ:CAPS) reported earnings of -$6.30 per share for Q1 2026, missing the consensus estimate of -$5.70. The report was announced on Wednesday, May 20, 2026.

Capstone Therapeutics reported revenue of $12.64 million for Q1 2026, against a consensus estimate of $10.80 million.

Capstone Therapeutics Earnings Headlines

Why my scanner is $7
Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full year, with no re-bills and nothing to install. The catch? He isn't trying to profit on the scanner itself. Poulos is betting that once you see it deliver the night's list, you'll want more of his work for years.tc pixel
See More Capstone Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Capstone Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Capstone Therapeutics and other key companies, straight to your email.

About Capstone Therapeutics

Capstone Therapeutics (NASDAQ:CAPS) was a biotechnology company focused on developing peptide-based therapies. Its lead investigational candidate was A6, a synthetic peptide studied for potential use in treating ovarian cancer.

The company was formerly known as OrthoLogic Corporation and adopted the Capstone Therapeutics name in 2008. Its work centered on advancing A6 rather than marketing an established portfolio of medicines.

View Capstone Therapeutics Profile